IPO - OS Therapies Inc

Form Type: S-1

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000121390025008855

Filing Summary: OS Therapies Incorporated is registering a total of 10,834,044 shares of common stock for resale by selling stockholders, which includes shares resulting from conversion of Series A Preferred Stock and warrants. This prospectus is associated with an initial public offering completed on July 31, 2024, where the company raised $6,400,000 in gross proceeds. The document outlines the company's mission to develop treatments for Osteosarcoma and reports on their lead product candidate, OST-HER2, currently undergoing clinical trials. It also mentions a recent asset purchase agreement with Ayala Pharmaceuticals to acquire HER2 related assets. The anticipated effective date of this registration is after necessary regulatory approvals and stockholder voting to occur by April 10, 2025. The company identifies itself as an emerging growth and smaller reporting company and discusses their financial condition, product pipeline, and risk factors associated with the investment.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000121390025008860

Filing Summary: OS Therapies Inc. has filed a Registration Statement on Form S-1 for the registration of 10,834,044 shares of common stock. This registration is related to shares issuable upon conversion of its Series A Senior Convertible Preferred Stock and the exercise of warrants sold in a private placement. The filing closely follows a previous registration (File No. 333-283171) that was declared effective on January 13, 2025, and includes updated executive compensation data for 2024 and details regarding the completion of a private placement carried out in December 2024 to January 2025. The filing aims to bring this information to the attention of the U.S. Securities and Exchange Commission and provides contact details for further clarifications.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000121390025002529

Filing Summary: OS Therapies Incorporated submitted a request to the U.S. Securities and Exchange Commission to accelerate the effectiveness of its Registration Statement on Form S-1 (No. 333-283171) to 4:00 p.m. Eastern time on January 13, 2025, or as soon as practicable thereafter. This action is part of the process for becoming publicly traded through an initial public offering (IPO). The request is being made by Spencer G. Feldman from Olshan Law, on behalf of the Company, and was signed by CEO Paul A. Romness.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025000850

Filing Summary: OS Therapies Incorporated has filed Amendment No. 2 to its Registration Statement on Form S-1 with the SEC, covering a maximum of 5,597,015 shares of common stock, including 165,746 shares as initial commitment shares and up to 450,000 shares as true-up shares. The primary purpose of this Amendment is to include details regarding the Company’s recent PIPE financing from December 2024. The Company expresses a strong interest in obtaining effectiveness of the Registration Statement during the week of January 6, 2025.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025000849

Filing Summary: OS Therapies Incorporated has filed an Amendment No. 2 to their Form S-1 Registration Statement with the SEC on January 3, 2025. This document outlines updates regarding their ongoing efforts to commercialize treatments for Osteosarcoma and other solid tumors. They aim to address significant needs in cancer treatment, particularly in children and young adults. Their lead product candidate, OST-HER2, is currently in a clinical trial with the expectation of topline results by the end of 2024 and intends to seek regulatory approval in 2025. The document also relates to a resale of up to 5,597,015 shares of common stock, including initial commitment shares and true-up shares, as part of an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC. The funds raised from the Equity Line of Credit and recent PIPE Financing, initiated with existing institutional investors, are intended to advance their clinical development programs. This filing does not involve the sale of securities by the company but facilitates the resale by the investor. OS Therapies shares are traded under the symbol 'OSTX' on NYSE American, following their IPO on July 31, 2024. As of January 2, 2025, the company shares closed at $4.18.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-27

Corporate Action: Ipo

Type: New

Accession Number: 000121390024103446

Filing Summary: On November 27, 2024, OS Therapies Incorporated filed Amendment No. 1 to its Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. This filing covers the registration of up to 5,597,015 shares of common stock, comprising initial commitment shares and true-up shares. The Amendment responds to comments from the SEC staff received on November 20, 2024, regarding the initial filing from November 12, 2024. The document outlines revisions made to specify the number of shares registered under an equity line financing with Square Gate Capital Master Fund LLC, which is now named as an underwriter within the filing. Additionally, concerns regarding Regulation M and its impact on market activities of the Selling Securityholder were addressed, clarifying that certain market-making activities would be prohibited while the equity line is in effect. Contact details for further inquiries were provided, establishing clear communication channels for any follow-up from the SEC staff.

Document Link: View Document